Reversible recurrent profound thrombocytopenia due to linezolid in a patient with multi-drug resistant tuberculosis: A case report

about

Reversible recurrent profound thrombocytopenia due to linezolid in a patient with multi-drug resistant tuberculosis: A case report

Item

http://www.wikidata.org/entity/Q58706270

description

im August 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована в серпні 2018

@uk

name

Reversible recurrent profound ...... nt tuberculosis: A case report

@en

Reversible recurrent profound ...... nt tuberculosis: A case report

@nl

type

Item

label

Reversible recurrent profound ...... nt tuberculosis: A case report

@en

Reversible recurrent profound ...... nt tuberculosis: A case report

@nl

prefLabel

Reversible recurrent profound ...... nt tuberculosis: A case report

@en

Reversible recurrent profound ...... nt tuberculosis: A case report

@nl

P1476

Reversible recurrent profound ...... nt tuberculosis: A case report

@en

P2093

Dan Wang

http://www.w3.org/2001/XMLSchema#string

Jian-Qing He

http://www.w3.org/2001/XMLSchema#string

Ming-Gui Wang

http://www.w3.org/2001/XMLSchema#string

P2860

The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria

Oxazolidinones, a new class of synthetic antituberculosis agent. In vitro and in vivo activities of DuP-721 against Mycobacterium tuberculosis

World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update.

Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program.

Mechanisms for linezolid-induced anemia and thrombocytopenia.

Retrospective cohort chart review study of factors associated with the development of thrombocytopenia in adult Japanese patients who received intravenous linezolid therapy.

Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000-06.

Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis.

Linezolid-induced thrombocytopenia in impaired renal function: is it time for a dose adjustment? A case report and review of literature.

Reduction of linezolid-associated thrombocytopenia by the dose adjustment based on the risk factors such as basal platelet count and body weight.

P304

e11997

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.1097/MD.0000000000011997

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30142839

http://www.w3.org/2001/XMLSchema#string

P921

thrombocytopenia

multiple drug resistance

P932

6113018

http://www.w3.org/2001/XMLSchema#string